SIOC English
有机化学
高级检索

有机化学 >

2013 , Vol. 33 >Issue 06: 1263 - 1272

DOI: https://doi.org/10.6023/cjoc201209028

综述与进展

银杏内酯衍生物和类似物的合成及PAFR和GlyR拮抗活性研究进展

  • 惠爱玲 ,
  • 吴泽宇 ,
  • 袁媛 ,
  • 周安 ,
  • 潘见
展开
  • a 合肥工业大学天然药物研究所 合肥 230009;
    b 安徽中医学院 安徽省中药研究与开发重点实验室 合肥 230038

收稿日期: 2012-09-20

  修回日期: 2012-12-19

  网络出版日期: 2012-12-25

基金资助

安徽省科技计划(No.11010401025)资助项目.

收起

Progress in Synthesis and Antagonistic Activities towards PAFR and GlyR of Ginkgolide Derivatives and Analogs

  • Hui Ailing ,
  • Wu Zeyu ,
  • Yuan Yuan ,
  • Zhou An ,
  • Pan Jian
Expand
  • a Institute of Natural Medicine, Hefei University of Technology, Hefei 230009;
    b Anhui Province Key Laboratory of Research and Development of Chinese Medicine, Anhui University of Traditional Chinese Medicine, Hefei 230038

Received date: 2012-09-20

  Revised date: 2012-12-19

  Online published: 2012-12-25

Supported by

Project supported by the Science and Technology Project of Anhui Province (No.11010401025).

Fold

摘要

银杏内酯是从银杏树中分离的二萜内酯成分, 它的结构是由6个五元环形成的笼状骨架并嵌有一个独特的叔丁基.研究已证实银杏内酯是血小板活化因子受体(PAFR)和甘氨酸受体(GlyR)的强有力拮抗剂, 它的结构变化将引起生物活性的改变.因此, 为了寻找更优的PAFR和GlyR拮抗剂, 人们合成了许多银杏内酯衍生物及类似物.重点综述了近年来银杏内酯类化合物的构效关系研究.

关键词： 银杏内酯衍生物; 银杏内酯类似物; 血小板活化因子受体; 甘氨酸受体; 构效关系

本文引用格式

惠爱玲 , 吴泽宇 , 袁媛 , 周安 , 潘见 . 银杏内酯衍生物和类似物的合成及PAFR和GlyR拮抗活性研究进展[J]. 有机化学, 2013 , 33(06) : 1263 -1272 . DOI: 10.6023/cjoc201209028

Abstract

Ginkgolides are diterpene trilactones with a cage-like skeleton consisting of six five-membered rings and a unique t-Bu group from Ginkgo biloba tree.Many studies have demonstrated that they are highly potent and selective antagonists of platelet activating factor receptor (PAFR) and glycine receptor (GlyR).Ginkgolide skeleton modifications may conduce to physiological activities variation.Therefore, many ginkgolide derivatives and analogs have been synthesized for the optimal antagonistic activities towards PAFR or GlyR.This review covers the structure-activity relationship studies of ginkgolide derivatives and analogs.

Key words： ginkgolide derivatives; ginkgolide analogs; platelet activating factor receptor; glycine receptor; structure-activity relationship

参考文献

[1] (a) Braquet, P.; Spinnewyn, B.; Braquet, M.Blood Vessels 1985, 16, 558. (b) Braquet, P.; Drieu, K.; Etienne, A.Actual.Chim.Ther. 1986, 13, 237.
[2] (a) Kondratskaya, E.L.; Lishko, P.V.; Chatterjee, S.S.; Krishtal, O.A.Neurochem.Int. 2002, 40, 647. (b) Kondratskayaand, E.L.; Krishtal, O.A.Neurophysiology 2002, 34, 155. (c) Jaracz, S.; Nakanishi, K.; Jensen, A.A.; Strφmgaard, K.Chem.Eur.J. 2004, 10, 1507. (d) Jensen, A.A.; Begum, N.; Vogensen, S.B.; Knapp, K.M.; Gundertofte, K.; Dzyuba, S.V.; Ishii, H.; Nakanishi, K.; Kristiansen, U.; Strφmgaard, K.J.Med.Chem. 2007, 50, 1610.
[3] Ivic, L.; Sands, T.T.J.; Fishkin, N.; Nakanishi, K.; Kriegstein, A.R.; Strφmgaard, K.J.Biol.Chem. 2003, 278, 49279.
[4] (a) Corey, E.J.; Kang, M.; Desai, M.C.; Ghosh, A.K.; Houpis, J.N.J.Am.Chem.Soc. 1988, 110, 649. (b) Corey, E.J.; Gavai, A.V.Tetrahedron Lett. 1988, 29, 3201. (c) Crimmins, M.T.; Pace, J.M.; Nantermet, P.G.; Kim-Meade, A.S.; Thomas, J.B.; Watterson, S.H.; Wagman, A.S.J.Am.Chem.Soc. 1999, 121, 10249.(d) Wu, Y.L.; He, Z.L.Highlights of Total Synthesis of Natural Products: Terpenes, Science Press, Beijing, 2010, pp.457～468 (in Chinese) (吴毓林, 何子乐, 天然产物全合成荟萃——萜类, 科学出版社, 北京, 2010, pp.457～468.)
[5] (a) Corey, E.J.; Gavai, A.V.Tetraheron Lett. 1989, 30, 6959.(b) Corey, E.J.; Rao, K.S.Tetrahedron Lett. 1991, 32, 4623.
[6] Braquet, P.; Esanu, A.GB 2211841, 1989[Chem.Abstr. 1990, 112, 76805].
[7] (a) Park, H.K.; Lee, S.K.; Park, P.U.; Kwak, W.J.WO 9306107, 1993[Chem.Abstr. 1993, 119, 138985]. (b) Park, P.U.; Pyo, S.; Lee, S.K.; Sung, J.H.; Kwak, W.J.; Park, H.K.; Cho, Y.B.; Ryu, G.H.; Kim, T.S.WO 9518131, 1995[Chem.Abstr.1995, 123, 314213]. (c) Park, P.U.; Pyo, S.; Lee, S.K.; Sung, J.H.; Kwak, W.J.; Park, H.K.; Cho, Y.B.; Ryu, G.H.; Kim, T.S.US 5541183, 1996 [Chem.Abstr. 1995, 123, 314213].
[8] Xu, R.S.Natural Products Chemistry, Science Press, Beijing, 2003, pp.397～409 (in Chinese).(徐任生, 天然产物化学, 科学出版社, 北京, 2003, pp.397～409.)
[9] Chen, J.Z.; Hu, L.H.; Jiang, H.L.The Fifth China—Japan Joint Symposium on Drug Design and Development, Chengdu, 1997, pp.81～82.
[10] Chen, J.Z.; Chen, K.X.; Jiang, H.L.; Gu, J.D.; Zhu, W.L.; Hu, Z.J.; Ji, R.Y.Sci.China, Ser.B 1998, 28, 316 (in Chinese). (陈建忠, 陈凯先, 蒋华良, 顾建德, 朱维良, 胡增建, 嵇汝运, 中国科学(B辑), 1998, 28, 316.)
[11] Chen, J.Z.; Hu, L.H.; Jiang, H.L.; Gu, J.D.; Zhu, W.L.; Chen, Z.L.; Chen, K.X.; Ji, R.Y.Bioorg.Med.Chem.Lett. 1998, 8, 1291.
[12] (a) Hu.L.H.; Chen, Z.L.; Xie, Y.Y.; Jiang, Y.Y.; Zhen, H.W.J.Asian Nat.Prod.Res. 2000, 2, 103. (b) Hu, L.H.; Chen, Z.L.; Xie, Y.Y.J.Asian Nat.Prod.Res. 2001, 3, 219.
[13] Hu, L.H.; Chen, Z.L.; Chen, X.F.; Xie, Y.Y.Pure Appl.Chem. 1999, 71, 1153.
[14] Hu, L.H.; Chen, Z.L.; Xie, Y.Y.; Jiang, Y.Y.; Zhen, H.W.Bioorg.Med.Chem. 2000, 8, 1515.
[15] Klebe, G.; Abraham, U.; Mietzner, T.J.Med.Chem. 1994, 37, 4130.
[16] Tong, W.; Lowis, D.R.; Perkins, R.; Chen, Y.; Welsh, W.J.; Goddette, D.W.; Heritage, T.W.; Sheehan, D.M.J.Chem.Inf.Comput.Sci. 1998, 38, 669.
[17] Zhu, W.L.; Chen, G.; Hu, L.H.; Luo, X.M.; Gui, C.S.; Luo, C.; Puah, C.M.; Chen, K.X.; Jiang, H.L. Bioorg.Med.Chem.2005, 13, 313.
[18] Strφmgaard, K.; Saito, D.R.; Shindou, H.; Ishii, S.; Shimizu, T.; Nakanishi, K.J.Med.Chem. 2002, 45, 4038.
[19] Jaracz, S.; Strφmgaard, K.; Nakanishi, K.J.Org.Chem. 2002, 67, 4623.
[20] Vogensen, S.B.; Strφmgaard, K.; Shindou, H.; Jaracz, S.; Suehiro, M.; Ishii, S.; Shimizu, T.; Nakanishi, K.J.Med.Chem. 2003, 46, 601.
[21] Strφmgaard, K.; Suehiro, M.; Nakanishi, K.Bioorg.Med.Chem.Lett. 2004, 14, 5673.
[22] Tanaka, K.; Kester, K.D.; Berova, N.; Nakanishi, K.Tetrahedron Lett. 2005, 46, 531.
[23] Tanaka, K.; Pimentel, M.; Berova, N.; Nakanishi, K.Bull.Chem.Soc.Jpn. 2005, 78, 1843.
[24] Ishii, H.; Dzyuba, S.V.; Nakanishi, K.Org.Biomol.Chem. 2005, 3, 3471.
[25] (a) Strφmgaard, K.; Nakanishi, K.Angew.Chem., Int.Ed.Engl. 2004, 43, 1640. (b) Nakanishi, K.Bioorg.Med.Chem. 2005, 13, 4987. (c) Dzyuba, S.V.; Bolshakov, S.; Li, J.; Nakanishi, K.Heterocycles 2005, 66, 743.
[26] Kato, E.; Howitt, R.; Dzyuba, S.V.; Nakanishi, K.Org.Biomol.Chem.2007, 5, 3758.
[27] Pietri, S.; Liebgott, T.; Finet, J.-P.; Culcasi, M.; Billottet, L.; Bernard-Henriet, C.Drug Dev.Res. 2001, 54, 191.
[28] Suehiro, M.; Simpson, N.R.; van Heertum, R.J.Labelled Compd.Radiopharm. 2004, 47, 485.
[29] Guo, C.J.; Ren, Y.; Qin, Y.L.; Zhang, Q.J.Asian Nat.Prod.Res. 2008, 10, 989.
[30] Liu, C.D.; Pan, S.H.; Mao, L.S.; Gu, P.C.; Wei, M.; Xu, H.Q.Chin.J.Nat.Med.2009, 7, 301.
[31] Deng, Y.; Fang, W.R.; Li, Y.M.; Cen, J.; Fang, F.; Lv, P.; Gong, S.B.; Mao, L.S.Eur.J.Pharmacol. 2009, 616, 43.
[32] (a) Wu, Z.Y.; Pan, J.; Yuan, Y.; Hui, A.L.; Yang, Y.; Zhou, A.; Tao, M.; Zhou, X.J. Med.Chem.Res. 2012, 21, 4028.(b) Pan, J.; Wu, Z.Y.; Yuan, Y.; Hui, A.L.; Yang, Y.Lat.Am.J.Pharm.2011, 30, 1167.(c) Pan, J.; Wu, Z.Y.; Hui, A.L.; Tao, M.Lishizhen Med.Mater.Med.Res. 2011, 22, 2397 (in Chinese).(潘见, 吴泽宇, 惠爱玲, 陶敏, 时珍国医国药, 2011, 22, 2397.) (d) Pan, J.; Yuan, Y.; Hui, A.L.; Zhou, A.; Wu, Z.Y.Chin.Pharm.Bull.2012, 28, 1435 (in Chinese).(潘见, 袁媛, 惠爱玲, 周安, 吴泽宇, 中国药理学通报, 2012, 28, 1435.) (e) Yuan, Y.; Pan, J.; Wu, Z.Y.; Hui, A.L.; Zhou, A.J.Chromatogr.Sci. 2012, 51, 266.(f) Chen, Y.Ph.D.Dissertation, Hefei University of Technology, Hefei, 2009 (in Chinese).(陈彦, 博士论文, 合肥工业大学, 合肥, 2009.) (g) Wu, Z.Y. Ph.D.Dissertation, Hefei University of Technology, Hefei, 2012 (in Chinese).(吴泽宇, 博士论文, 合肥工业大学, 合肥, 2012.) (h) Zhou, X.J. M.S.Thesis, Hefei University of Technology, Hefei, 2012 (in Chinese).(周小健, 硕士论文, 合肥工业大学, 合肥, 2012.)
Options
文章导航

/

〈 〉